By OPEN MINDS Circle
The Oklahoma Medicaid program and Pear Therapeutics entered a value-based access agreement for Pear’s reSET and reSET-O prescription digital therapeutic (PDT) addiction treatments. The agreement went into effect on January 1, 2022, for beneficiaries enrolled in the Oklahoma Health Care Authority (OHCA) SoonerCare program. OHCA has not disclosed the specific performance and outcomes-based benchmarks being monitored under this agreement, or the terms of payment. The agreement leverages the Oklahoma State Medicaid plan amendment to implement voluntary Medicaid value-based drug purchasing agreements. About 44% of the 1.2 million people are enrolled in SoonerCare are over age 21.
The reSET PDT is a software application intended to provide cognitive behavioral therapy, as an adjunct to a contingency management system, for people 18 years of age and older, who are currently enrolled in outpatient addiction treatment under the supervision of a clinical professional. reSET is indicated as a 12-week (90 day) prescription-only treatment for consumers with addiction disorder, who are not currently on opioid replacement therapy, who do not abuse alcohol solely, or who do not abuse opioids as their primary substance of abuse. reSET is intended increase the consumer’s abstinence level and increase retention in an outpatient treatment program.
The reSET-O PDT is a 12-week (84 day) software application intended to increase treatment retention of consumers with opioid use disorder (OUD) in outpatient treatment. The PDT provides cognitive behavioral therapy, as an adjunct to outpatient treatment that includes transmucosal buprenorphine and contingency management, for consumers 18 years or older who are currently under the supervision of a clinical professional.
Pear Therapeutics develops and markets PDTs for multiple therapeutic areas. Three of its PDTs have been authorized by the FDA for commercial use; they are reSET®, reSET-O® for opioid addiction, and Somryst® for the treatment of chronic insomnia. The PDTs are designed to engage consumers in treatment and provide tracking tools for clinical professionals. Its PDTs are designed to collect real world data for use by prescribing clinical professionals and for population health management by payers and health systems.
Contact information: Meara Murphy, Senior Director, Corporate Communications, Pear Therapeutics, 201 Mission Street, San Francisco, California 94105; Email: meara.murphy@peartherapeutics.com; Website: https://peartherapeutics.com/
Contact information: Katelynn Burns, Media Relations Professional, Oklahoma Health Care Authority, 4345 North Lincoln Boulevard, Oklahoma City, Oklahoma 73105; 405-443-9415; Email: katelynn.burns@okhca.org; Website: https://www.okhca.org/